NCT01372540View on ClinicalTrials.gov

Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

February 24, 2012

Primary Completion Date

May 16, 2019

Study Completion Date

May 16, 2019

Conditions
Plasma Cell LeukemiaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Carfilzomib

Given IV

DRUG

Filanesib

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01372540 - Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | Biotech Hunter | Biotech Hunter